Updates in Targeted Therapies for ALK+ and ROS1+ NSCLC from ESMO 2024 - Episode 2

Data for NVL-655 in Advanced ALK+ NSCLC and Solid Tumors from the ALKOVE-1 Trial

,

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Testing for ALK Fusions and ROS1 Rearrangements in NSCLC
    Now Viewing
    EP. 2: Data for NVL-655 in Advanced ALK+ NSCLC and Solid Tumors from the ALKOVE-1 Trial
    EP. 3: Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors
    EP. 4: Preclinical CNS Data for Zidesamtinib and Other ROS1 Inhibitors
    EP. 5: Progression Patterns and Subsequent Therapies after Lorlatinib in ALK+ NSCLC
    EP. 6: The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC
    EP. 7: Lorlatinib in ROS1+ Advanced NSCLC After Crizotinib and Chemotherapy
    EP. 8: Future Research Directions in ALK+ and ROS1+ NSCLC
    x